Will Lifyorli Year 1 US revenue annualize above $50M by the Q3 2026 10-Q?

The resolution criteria require Q3 2026 10-Q to disclose Lifyorli US revenue of $12.5M+ in that single quarter, reflecting a $50M+ annualized run rate. Approval date was 2026-03-25. Q3 2026 covers July-September 2026 — this is the first full post-approval quarter. First-ever Corcept oncology launch, center activation and J-code assignment timelines typically 6-12 months for new specialty oncology agents. CFO characterized Lifyorli as 'only a small portion' of FY26 guidance ($900M-$1B); taking this literally as 3-6% implies $27-60M for full FY26, not Q3 alone. Achieving $12.5M in a single quarter (Q3) requires rapid ramp-up atypical of first-ever launches. Base rate for platinum-resistant ovarian cancer launches with OS benefit reaching $50M annualized in Year 1 is approximately 35-45%, but concentrated toward H2 2026 and 2027 rather than Q3. Tilted below base rate at 0.38.

Counterbalancing the 'first launch, slow ramp' concerns: (1) oncology commercial team was built in 2025 BEFORE approval, so infrastructure is in place; (2) 4-month PDUFA acceleration is a process signal indicating FDA and company both moved aggressively; (3) +4.1 month OS benefit is strong clinical differentiation in platinum-resistant ovarian cancer, where standard of care is limited; (4) orphan drug designation supports aggressive pricing (~$150K+/year). For a single-quarter revenue threshold of $12.5M in Q3 2026 (Jul-Sep, the second full post-approval quarter), the sell-in pattern matters: specialty oncology launches often see $5-15M in Q2 (sell-in to centers) and $10-25M in Q3 if center activation proceeds normally. The question mainly tests whether center activation hits critical mass by September 2026. Base rate adjusted upward to ~0.42.

Decomposing the Year 1 revenue trajectory: Approval March 2026 -> Q2 2026 (Apr-Jun): sell-in phase, ~$3-8M -> Q3 2026 (Jul-Sep): ramping centers + reimbursement stabilization, ~$7-18M -> Q4 2026 (Oct-Dec): momentum quarter, ~$12-30M. The $50M annualized threshold measured at Q3 10-Q requires $12.5M+ in the single quarter (Jul-Sep 2026). This is at or slightly above the center of the Q3 range estimate. Layering in structural frictions: (a) Medicare J-code assignment typically 6-9 months post-approval = September-December 2026 window; coding delays depress Q3 bookings; (b) nab-paclitaxel partner drug availability required for combo therapy; (c) 'sell-in to first 20-30 centers' dynamic rather than broad prescriber base. The question is whether aggressive launch execution can overcome these frictions. Slightly below 50/50: 0.35.

Base rate for specialty orphan oncology drugs reaching $50M annualized in Year 1 is 40-50%, but that's typically measured end of Year 1 (not 6 months in). Q3 2026 is only 2 full quarters post-approval. First-ever Corcept oncology launch faces infrastructure gap despite commercial team build-out. Management's 'only a small portion' framing implies $30-60M for full FY26, with back-loading. Hitting $12.5M in Q3 alone (implying an already-$50M run rate by end of Q3) is aggressive. Net: 0.40.

The market clearly underprices Lifyorli ($200M credit vs $500M-$2B typical) which is the thesis tension. If execution is average-or-above for a specialty oncology launch with OS benefit, reaching $12.5M in Q3 2026 is achievable. Counterweights: (1) Corcept has no prior oncology commercial track record, (2) CFO's 'small portion' characterization is their best estimate. The probability is not low because approval was 4 months early (pulling launch forward), infrastructure was built ahead, and the +4.1 month OS is strong signal. Net: 0.45.

The strict resolution criteria - $12.5M in Q3 2026 ALONE, not cumulative or averaged - is the hardest hurdle. Specialty oncology launches often look like: Q2 $3-7M (stocking), Q3 $8-15M (early adoption), Q4 $15-25M (momentum), Q1 $20-35M (steady state). Only in above-average-execution scenarios does Q3 hit $12.5M+. The 'first launch' learning curve and combination-therapy coordination costs typically put Q3 at the lower end of this distribution. Settle at 0.36.

Lifyorli approved late March 2026; Q3 2026 is second full post-approval quarter. Center activation, J-code assignment, nab-paclitaxel coordination mean launches typically hit momentum in Q4/Q1. $12.5M in Q3 alone is above-average trajectory but possible. Net 0.38.

Pro: strong OS benefit, orphan pricing, pre-built commercial team, 4-month PDUFA acceleration. Con: first oncology launch, Q3 = early ramp, combo therapy adds friction. Probability is meaningfully below coin-flip but not negligible at 0.42.

CFO explicitly characterized 2026 Lifyorli as 'only a small portion' of $900M-$1B guide. Taking that at face value means ~3-5% FY26 contribution, i.e., $27-45M full year, with back-loading into Q4. Q3 alone at $12.5M implies aggressive ramp. Probability 0.33.